Fabtech Technologies Ltd

Fabtech Technologies Limited's investor presentation for Q2 and H1FY27 highlights strong EBITDA growth, with EBITDA (including other income) increasing by 110% to ₹155.7 million in Q2 FY27 compared to Q1 FY27. The company reported revenue of ₹920.9 million in Q2 FY27, with a total income of ₹975.4 million and total expenditure of ₹819.7 million. The presentation noted that revenue and profitability are expected to improve in H2 FY27 as planned project milestones translate into execution. Management remains confident of achieving an Adjusted PAT* margin objective of 8–9% for FY27. The company has a healthy order book of ₹900 crore as of September 30, 2026, with additional prospective orders from Africa and Saudi Arabia amounting to ₹800-850 crore. Strategic priorities include accelerating project delivery in Africa and the UAE, advancing capabilities in cell and gene therapy facilities, and exploring operational opportunities in Europe. The company's consolidated income statement shows a revenue CAGR of 28% and an earnings CAGR of 22% over FY23–FY26, with a closing unexecuted order book of ₹900 crore at the end of FY26. The presentation also outlines the company's global presence across 62+ countries and its focus on integrated execution, in-house manufacturing, and strategic partnerships to drive growth.

The presentation emphasizes strong financial performance, growth in EBITDA, confidence in achieving profitability targets, and strategic expansion plans.